TABLE 2.
Antiviral spectrum of AZ5385a
| Virus | Cells | EC50 (µM) | CC50 (µM) | SI (CC50/EC50) |
|---|---|---|---|---|
| HRV-A type 16 | H1-HeLa | 3.6 | >20 | >5.5 |
| HRV-B type 14 | H1-HeLa | >20 | >20 | |
| Poliovirus type 1 | GMK AH1 | >40b | 23 | |
| RSV strain A2 | HEp-2 | 0.4 | >50 | >125 |
| SARS-2 coronavirus isolate DE-P3 | Vero | ≥40c | >50 | |
| HSV-2 strain 333 | GMK AH1 | >40b | 23 |
a
The compound was tested for antiviral activity by the MTS-based colorimetric assay (HRV-16 and HRV-14), the viral plaque assay (RSV), and by the cytopathic effect inhibition assay (poliovirus, HSV-2, and SARS-2 coronavirus). The cytotoxicity of the compound for different cell lines was tested by using the MTS reagent, and the CC50 was interpolated from the dose-response curve.
b
Lack of antiviral activity at the highest non-cytotoxic concentration tested.
c
Partial inhibition (~50%) of the virus-induced CPE at 40 µM.